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Abstract
Seven days after activation with concanavalln A and irradiated spleen cells, murine CD4+ T cells
were re-stlmulated with lonomycln and phorbol 12-myristate 13-acetate (PMA). IL-2 and IL-4 were
determined In the supernatant. When cholera toxin, forskolin together with phosphodlesterase
Inhibitors or dlbutyryl-cAMP were added at the time of re-stimulation, a dose-dependent increase
of IL-4 and IL-5 release was noted. IL-2 was down-regulated as reported before. The up-
regulatlon of IL-4 and the down-regulation of IL-2 correlated with an increase of IL-4 mRNA and a
decrease of IL-2 mRNA as determined by seml-quantltative reverse trarwcrlptase polymerase
chain reaction. Similar results were found with prostaglandin E, using PMA and tonomycln or
plate-bound antl-CD3 antibody as re-stimulants. These results suggest that, In activated CO4+
T cells, cAMP-elevating agents induce a switch of lymphoklne production towards a T^-JIke
phenotype through regulation at the transcrlptlonal level. This Is supported by the fact that
complex formation between a synthetic nuclear factor of activated T cells (NF-AT) binding site
from the IL-2 promoter and nuclear extracts was decreased when cholera toxin was added to
re-actlvated CD4* T cells, suggesting that cholera toxin and cAMP down-regulate IL-2 expression
via decreased NF-AT binding. Finally, since IL-4 has been reported to amplify IL-4 release from
activated CD4+ T cells, the autolnductlon of IL-4 may very well function via cAMP.
Introduction
It is well documented that the function of Th cells depends on
their secreted rymphokines (1). On this basis, Th cells have been
classified in two subsets, Th1 and T^ , each of them playing a
specific role in the generation of an immune response. Activated
Th1 cells produce mainly IL-2 and IFN-7 and induce cell-
mediated immune responses, such as delayed-type hyper-
sensitivity reactions, whereas activated T£ cells, which produce
IL-4 and IL-5, will rather promote a humoral-type response (2).
Furthermore, this functional separation of Th cells has been
shown to be of great biological relevance since Th1 and Th2
cells were demonstrated to be differentially involved in both
murine and human immunopathologic processes (3,4). Several
authors have therefore attempted to elucidate the factors that
regulate the differentiation of primary Th cells into Th1 and 1^2
cells, and to analyze the regulation of their lymphokine
production.
It was shown that, upon antigenic stimulation, Th cells first
acquire an unrestricted pattern of lymphokine production (1L-2*.
IFN-7+. IL-4* and IL-5+) (4,5). At the clonal level, T cells with
an unrestricted lymphokine pattern are named Th0 cells. These
ceils are able to differentiate into both Th1 and T ^ subsets (6,7).
Factors which promote the induction of Th1 cells are transform-
ing growth factor-0 and IL-12 (8,9). The presence of IL-4 (7,10,11)
and TCR occupancy (12) are required for Th2 cell induction.
Several groups have studied the role of various intracellular
signalling pathways for the expression of Th subset typical
rymphokines. Gajewski ef a/, showed that lymphokine production
by Th1 clones was more sensitive to inhibition by cholera toxin
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(CT) and cAMP than was lymphokine production of T ^ clones
(13). Moreover, it was shown that CT and forskolin (FSK) inhibited
TCR-triggered IL-2 production and proliferation in Th1 cells,
while the same reagents failed to block IL-4 production and
proliferation in T ^ cells (14). Both IL-2 and IFN-7 production
were reduced in the presence of the cAMP-elevating agents
prostaglandin E2 (PGE2) when added to Th0 clones or short-
term T cell lines. IL-4 levels were not affected by PGE2 (15).
Similar results were obtained with the EL-4 cell line: cAMP
diminished IL-2 mRNA but did not affect IL-4 mRNA levels (16).
These results suggested that cAMP-dependent signaling events
may selectively regulate Th1 lymphokines.
Because most previous work was done with cells that possess
a fixed lymphokine pattern, we investigated the effect of cAMP
and cAMP-elevating agents on IL-4 production by polyclonal
CD4+ T cells expressing an unrestricted and non-fixed
lymphokine pattern. Here we show that, when CD4+ T cells
were re-activated with phorbo) 12-myristate 13-acetate (PMA) and
ionomycin, both cAMP and cAMP-elevating agents could indeed
affect Th2 lymphokines: these reagents increased IL-4 bioactivity
released into the supernatant and IL-4 mRNA accumulation as
determined by semi-quantitative reverse transcriptase polymerase
chain reaction (RT-PCR). IL-5 production was similarly increased
by cAMP-elevating agents. We also show that increased IL-4
production was induced by the naturally occurring cAMP-
elevating agent PGE2 in conjunction with either PMA and
ionomycin or anti-TCR stimulation. Finally a complex from nuclei
of activated CD4+ T cells binding to an oligonucleotide
containing the nuclear factor of activated T cells (NF-AT) binding
sequence from the IL-2 promoter was decreased by cAMP,
suggesting that cAMP may down-regulate IL-2 by decreasing
nuclear factors binding to the NF-AT site.
Methods
Culture medium and reagents
Cells were cultured in Iscove's modified Dulbecco's medium with
L-glutamine, supplemented with 1 % MEM non-essential amino
acids, 100 U/ml penicillin, 100 /ig/ml streptomycin and 2 mM
L-glutamine (all from Gibco, Grand Island, NY), 10% heat-
inactivated FCS, (Gibco, Munich, Germany), 1 mM sodium
pyruvate (Fluka, Buchs, Switzerland) and 2x10~ 5 M
2-mercaptoethanol (Sigma, St Louis, MO). PMA, CT, dibutyryl-
cAMP (Bt2-cAMP), 3-isobutyM-methylxanthine (IBMX), PGE2
and FSK were purchased from Sigma; concanavalin A (Con A)
was from P-L Biochemicals (Milwaukee, IL) and ionomycin from
Calbiochem (La Jolla, CA). The phosphodiesterase (PDE) inhibitor
RO 20-1724 (17) was kindly provided by Hoffmann-La Roche
(Basel, Switzerland). The mAbs to MHC class II (M5/114.15.2),
CD8 (5.3-6.72) and mouse anti-rat x chain (MAR 18.5) were
obtained from the American Type Culture Collection (Rockville,
MD). For phenotyping, cells were stained with mAb anti-
CD4 - phycoerythrin conjugate and anti-CD8 - FITC (Becton-
Dickinson, Mountain View, CA) and analysed on a FACScan
(Becton-Dickinson).
Preparation of CD4+ activated T cells
Female BALB/c mice (IFFA-Credo, Arbresle, France) were used
in all experiments. Activated CD4+ T cells were obtained in 7
days of culture as follows. CD4+ T cells were purified as
described (18). Briefly, lymph node cells were purified by passage
over a nylon wool column, and incubated on ice for 30 min with
mAb to MHC class II and CD8, followed by MAR-18.5 and rabbit
tow-tox M complement (1/10; Cedarlane, Hornby, Ontario,
Canada). CD4+ T cells (5X106) (>98% CD4+, < 1 % CD8+,
< 1 % MHC class II+ and non-responsive to Con A atone) were
then stimulated in 10 ml of culture medium with Con A (2 /ig/ml),
50 U/ml human rhlL-2 (a generous gift from Dr C. R. Franks,
Eurocetus, Amsterdam, Netherlands) and 107 3000 rad-
irradiated splenocytes. Three days later, the culture was divided
in six parts and supplemented with fresh medium containing
rhlL-2. On day 6, cells were washed and cultured in rhll_2-con-
taining medium for a further 24 h. On day 7, these activated
CD4+ T cells were washed again and re-stimulated for
lymphokine production.
T cell stimulation
Activated CD4+ T cells (lOS/well) were seeded in 96-well tissue
culture plates (Costar, Cambridge, MA) filled with 200 /J culture
medium ± stimulator/inhibitor at the indicated final concentra-
tions. After 30 min incubation at 37°C, PMA (1 ng/ml) and
ionomycin (1 /tg/ml) were added for stimulation. Supernatants
were harvested after 24 h and stored at - 20°C until lymphokine
analysis. For anti-CD3 stimulation, wells were coated with 50 /J
of affinity purified mAb 145 2C11 (19) 3 /ig/ml in PBS for 2 h
at 37°C. Wells were then washed three times with 150 /J of sterile
PBS before addition of culture medium ± the indicated reagents
and lastly cells. For RNA analysis, 4 - 1 0 x 106 activated T cells
were first incubated for 30 min at 37°C at a density of
2 - 3 x i O 6 cells/ml with the indicated reagents, and then
stimulated for 6 h (unless stated otherwise) with PMA and
ionomycin. The 6 and 24 h supernatants (obtained from parallel
cultures) were kept for lymphokine analysis.
Bioassays
To measure the production of IL-2 and IL-4, a specific lymphokine
assay was used (18). Briefly, 5x 103 CTLL cells responding to
both IL-2 and IL-4 (a kind gift of Dr E. M. Shevach, LI, NIAID,
NIH, Bethesda, MD) were incubated in flat-bottomed 96-well
tissue culture plates (Costar) with appropriate serial dilutions of
lymphokine-containing culture supernatants in the presence of
either S4B6, a neutralizing mAb to mouse IL-2, kindly provided
by Dr T. Mosmann (DNAX, Palo Alto, CA) (20), as a 1/1000
dilution of ascites or a 1/100 dilution of a Tecnomouse™
(Tecnomara, Switzerland) supernatant, 11B11, a neutralizing mAb
to mouse IL-4, kindly provided by Dr W. E. Paul, LI, NIAID, NIH,
Bethesda, MD (21), as a 1/1000 dilution of ascites, both mAb
or no mAb. Internal standards for IL-2 and IL-4 calibrated with
rhlL-2 or with murine rlL-4 (obtained from Dr W. E. Paul),
respectively, were incubated in parallel. Proliferation was
assessed by [3H]methyl-thymidine incorporation after pulsing
the cultures (0.5 pCi/well) for the final 6 - 8 h of the 24 h culture
period. Sample points lying on the linear part of the
dose - response curve were used to calculate IL-2 and IL-4
activities. The detection of IL-2 and IL-4 by the CTLL cells was
not affected by PMA and ionomycin, nor by the presence of CT,
FSK, IBMX, RO-20-1724 or Bt2-cAMP at working concentra-
tions. IL-5 in culture supernatants was determined by ELISA,
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using the anrj-IL-5 rat mAb TRFK4 (5 pg/ml for coating)
and TRFK5 (biotin-labeled, 1 pg/ml, kindly donated by
Dr R. L. Coffman, DNAX, Palo Alto, CA) (22), as previously
described (23). The Student's f-test was used for statistical
analysis.
RNA analysis
At the indicated time points, CD4+ T cells were harvested,
transferred to Eppendorf tubes and centrifuged. Total cellular
RNA was recovered after cell lysis in 1 ml of guanidine thio-
cyanate buffer by acid phenol extraction and isopropanol
precipitation (24). The yield was 8 ± 2 pg of total RNA/106
CD4+ T cells. The integrity of the RNA was assessed by
analysis of ribosomal RNA on 1 % agarose gel electrophoresis.
The efficiency of the reverse transcription (RT) was verified by
detection of the dihydrofolate reductase (DHFR) mRNA (25) with
RT-PCR (26). In brief, RT-PCR was done as follows for all the
mRNA tested: - 2 pg of total cellular RNA was retrotranscribed
after heat denaturation and annealing with oligo(dT) primers
(15-mer, Boehringer Mannheim, Rotkreuz, Switzerland) in the
presence of 200 U Moloney murine leukemia virus reverse
transcriptase (Gibco), 40 U RNAsin (Promega, Madison, W1),
5 mM DTT and 200 pM of each deoxynucleoside triphosphate
in 50 pi for 1 h at 37°C. The reactions were stopped by heating
inactivation for 5 min at 95°C, diluted 1:10 with water and stored
at -20°C until use. Either 5 pi (DHFR) or 1 pi (IL-2 and IL-4) of
one-tenth diluted cDNA were then amplified in a DNA thermo-
cycler (Perkin-Elmer, Norwalk, CT) with 200 pM of each
deoxynucleoside triphosphate, 50 U/ml of Taq polymerase
(Promega) diluted in the buffer supplied by the manufacturer,
and 500 nM of both upstream and downstream primer, in a
volume of 20 pi. Each PCR cycle consisted of a denaturation step
(94°C, 30 s), an annealing step (60°C, 30 s) and an elongation
step (72°C, 30 s). For the first cycle only, the duration of the
denaturation step was 3 min and for the final step only, the
duration of the processing step was 10 min. A total of 35 cycles
for DHFR and 30 cycles for IL-2 and IL-4 detection, corres-
ponding to the linear portion of the amplification curve, was used
in all experiments.
Each RT-PCR included negative controls for (i) RNA extraction:
lysis buffer alone treated as a normal sample; (ii) RT: RT reactants
without RNA; (iii) PCR: PCR reactants without cDNA.
All the necessary precautions against contamination of PCRs
were rigorously observed (27). The primers had the following
sequences: DHFR upstream 5'-CTCAGGGCTGCGATTTCGC-
GCCAAACT-3', downstream 5'-CTGGTAAACAGAACTGCC-
TCCGACTATC-3', amplifying a 447 nucleotide sequence; IL-2
upstream 5'-GTCAACAGCGCACCCACTTCAAGC-3', down-
stream 5'-GCTTGTTGAGATGATGCTTTGACA-3', amplifying a
450 nucleotide sequence; IL-4 upstream 5'-ACGGAGATGGA-
TGTGCCAAACGTC-3', downstream 5'-CGAGTAATCCATTT-
GCATGATGC-3', amplifying a 279 nucleotide sequence.
Amplimer sequences were chosen from separate exons of the
genes so that products from cDNA amplification could be
distinguished from products derived from any contaminating
genomic DNA. The specificity of the PCR was confirmed by
restriction site analysis of the amplified cDNA, which generated
restriction fragments of the expected size for all cytokines tested.
RT-PCR amplified products of the DHFR house-keeping gene
were first loaded on a gel to allow normalization using scanning
densitometry. Shown gels represent the reloaded normalized
amounts of DHFR amplified products together with equal
amounts of IL-2 and IL-4 amplifications for each culture condition.
DNA binding assays
Nuclear extracts from reactivated CD4+ T cells were prepared
as described (28). The oligonucleotides comprising the murine
IL-2 NF-AT and the NF-IL-2-A site (29) as well as an
oligonucleotide containing an AP-1 consensus sequence,
underlined (30):
NFVkT (-285O -270)5'caglCCCCAAAGAGGAMATTTGTTTCATACAGl 3-
3- • GGGGTTTCTCCTTTTAAACAAAGTATGT(*gac5'
5'caglGAAAATATGTGTAATATGTAAAACATCGt 3-
y aCTTTTATACACATTATACATTTTGTAGCqafcS'
NR.-S-A (-W ID -66)
yqaglGCTCGGGTAGGGGTGACTCACCGGQTGAACGGGGGCATCTCGACTCG t 3*
31 •CGAGCCCATCCCCACTGAGTGGCCCACTTGCCCCCGTAGAGCTGAGC *•£ y
The oligonucleotides were purified, annealed to yield a double-
stranded DNA fragment and subsequently labeled by a fill-in
reaction using [a-32P]dCTP and T7 DNA polymerase
(Pharmacia).
Nuclear extracts (5 pi) from re-activated CD4+ T cells were
incubated with ~ 1 ng of labeled probe (25,000 c.p.m.) for 30 min
at room temperature in a total volume of 20 pi binding buffer
[10 mM HEPES, pH 7.9, 80 mM KCI, 1 mM DTT, 0.2 pg/pl
pory(dl-dC) and 5% glycerol]. The protein-DNA complexes
were resolved on a 5% non-denaturing potyacrylamide (29:1)
gel at room temperature in 0.5 x TBE (pre-run for 2 h), and the
dried gel was exposed to a Kodak XAR film.
Results
Freshly isolated and highly purified resting CD4+ cells (>98%
by flow cytometry) were stimulated with Con A and irradiated
syngeneic spleen cells in the presence of IL-2. On day 6,
activated CD4+ cells were washed and incubated for a further
24 h in medium supplemented with rhlL-2. This procedure lead
to an 8- to 12-fokJ increase of cells that were >98% CD4+.
These cells are subsequently referred to as 'activated CD4+
T cells'. When stimulated with PMA and ionomycin, they
produced an unrestricted rymphokine pattern with regard to IL-2,
IFN-7, IL-4 and IL-5 (data not shown). PMA alone (1 ng/ml) was
ineffective for the production of either cytokine and ionomycin
(1 pg/ml) alone induced lower IL-4 production than in conjunction
with PMA (data not shown). Together, these results indicated that
in activated CD4+ T cells, high production of both IL-2 and IL-4
was achieved through the pharmacological triggering of both the
protein kinase C (PKC) and calcium-dependent pathways, as
described before (31).
In PMA- and ionomycin-re-stimulated CD4+ T cells, CT
dramatically decreased IL-2 production (Fig. 1). In contrast, PMA-
and ionomycin-induced IL-4 production was enhanced. This
increase of IL-4 production was dose-dependent and repro-
ducible in more than five similar experiments, in which a maximal
3- to 8-fold increase of IL-4 was observed at 1 ng/ml of CT. The
presence of CT, PMA or ionomycin in the supernatant did not
interfere with the biological detection of IL-2 and IL-4, even at
the highest tested concentration (supernatant dilution 1:20). This
was also the case for all modulators subsequently used in this
report.
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Since lymphokine production in T cells was shown to be
regulated at the transcriptional level, we verified whether CT
affected IL-2 and IL-4 mRNA accumulation (Fig. 2). In parallel
to cytokine production, IL-2 mRNA was clearly decreased in cells
incubated in the presence of CT, whereas IL-4 mRNA was
increased. Although the RT-PCR method used here is only semi-
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Fig. 1. CT differentially regulates IL-2 and IL-4 production in activated
CD4+ T cells. Activated CD4+ T cells (10s) were resfmulated with PMA
and ionomycin in 200 fii culture medium containing CT at the indicated
final concentrations. Lymphokine concentrations represent the means
± SD of the 24 h supernatants of triplicate cultures and are expressed
as units per 106 ceils. Presented data are representative of five similar
experiments. 'P < 0.05, "P < 0.01.
quantitative, the opposite effects of CT on IL-2 and IL-4 mRNA
were clear, reproducible in all experiments, and correlated with
IL-2 and IL-4 biological activities.
Most effects of CT have been shown to be mediated through
an increase of cAMP. The ADP ribosylation by CT of the Gs,
protein of the adenylate cyclase complex induces a prolonged
activation of the adenylate cyclase and thus the hydrolysis of ATP
leading to increased levels of intracellular cAMP (32). In order
to confirm that our findings in activated CD4+ T cells stimulated
in the presence of CT were also mediated by an increase of
cAMP, we next used FSK, a direct activator of adenylate cyclase.
In dose-response experiments, FSK decreased IL-2 in PMA-
and ionomycin-reactivated CD4+ T cells with a 50% inhibition
at - 3 - 1 0 fiM, whereas IL-4 production was slightly increased
only at doses from 10 to 30 /iM (data not shown). Higher doses
of FSK were toxic for the cells and resulted in complete inhibition
of both cytokines. We further investigated whether CT and FSK
altered the kinetics of IL-2 and IL-4 mRNA and protein production
(Fig. 3). At indicated time points, cultured wells containing
2x10* activated CD4+ T cells/ml were harvested, and assayed
for lymphokine production and mRNA expression. CT and FSK,
used here at concentrations (1 ng/ml and 30 /»M respectively)
previously determined to maximally influence the lymphokine
pattern of activated CD4+ T cells, similarly reduced IL-2
production. The increase of IL-4 by FSK was, however, far less
than with CT (Fig. 3A). IL-2 mRNA transcripts were diminished
in the presence of CT (Fig. 3B). Decreased IL-2 mRNA in the
presence of FSK was clear only at 1 and 6 h. An increase of
Protein mRNA
« »•• IL-2
(30cj)
DHFR
(JOtjr)
IL-4
Ofejr)
(-) P/I 10 1 0.1
CT
Flfl. 2. CT increases IL-4 mRNA expression In activated CD4+ T cells. Cell (2x 106) were stimulated with PMA and ionomycin in the absence
(P/I) or presence of 10, 1 or 0.1 ng/ml CT. Protein: lymphokine levels are from 24 h supernatants of parallel cultures and are expressed as units
per 10* cells. Standard deviation of triplicate lymphokine determination was <9W) of the mean. Results are repesentative of three similar experiments.
mRNA: after 6 h, cells were harvested for total RNA extraction and reverse transcription. cDNA corresponding to 20 ng of total RNA was then used
tor PCR amplification with specific primers. After normalization with PCR amplification of the DHFR gene, as described in Methods, aliquots of the
amplified cDNA were electrophoresed on 2% agarose gets in the presence of ethidium bromide.
B
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Fig. 3. Effect of FSK and CTon the productionof IL-2 and IL-4 from actrvatedOD4+Tc»fls. Activated CD4+T cells (2x10^ cells/mO were stimulate
with PMA and ionomycin in the absence of in the presence of 30 pM FSK or 1 ng/ml CT. Results represent the lymphokine content of supematants
(A) and RT-PCR amplifications of the corresponding mRNA (B), harvested at indicated times. RT-PCR amplification of the DHFR mRNA was used
for normalization, as described in Methods. Differences in lymphokine content of CT- and FSK-treated versus untreated culture supernatants were
statistically significant: P < 0.05 at 2 h and P < 0.01 at 4 h and after. Data are representative of three experiments for CT. For FSK, three experiments
for lymphokine analysis and two for RNA yielded similar results.
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Fig. 4. Synergistic influence of FSK and the POE inhibitor RO 20-1724
on IL-2 and IL-4 production. Activated CD4+ T cells (105) were re-
stimulated with PMA and tonomydn in 200 /J culture medium containing
(A) CT (ng/ml), (B) FSK fciM), (C) RO 20-1724 0»M) or (D) 10 pM FSK
combined with RO 20-1724 at the indicated concentrations 0«M).
Lymphokine concentrations represent the means ± SD of the 24 h
supernatants of triplicate cultures and are expressed as units per 106
ceils. One of three similar experiments is shown. *P < 0.05, "P < 0.01,
as compared with the negative control of each group.
IL-4 mRNA was seen with CT at all time points. However, the
2-fdd increase of IL-4 bioactivity in FSK-incubated wells was not
detectable by semi-quantitative RT-PCR. To determine whether
the discrepancy between the effects of CT and FSK on IL-4
modulation could be explained by a difference in cAMP
accumulation or by other effects of CT such as its effect on the
non-catalytic B subunit (33,34), activated CD4+ T cells were
re-stimulated in the presence of the PDE inhibitor RO 20-1724,
highly specific for cAMP PDE (17). As expected, 1-30 /iM RO
20-1724 decreased IL-2 in a dose-dependent manner. IL-4
production was, however, left unchanged (Fig. 4C). When the
combination of both FSK and RO 20-1724 (Fig. 4D) was used,
a synergistic effect was seen since the combination could
enhance IL-4 to levels close to those observed in the presence
of CT (Fig. 4A) and abrogated IL-2 release. A statistically signifi-
cant synergy on IL-2 reduction and IL-4 increase was also
observed with the combination of FSK and the less specific PDE
inhibitor IBMX (data not shown). Since the combination of an
activator of the adenylate cyclase combined with PDE inhibitors
could reproduce the CT effect, it is likely that the modification
of IL-2 and IL-4 production we observed with CT was mainly
mediated through an increase of cAMP. These experiments also
indicated that IL-2 was more sensitive than IL-4 to cAMP-etevating
agents in activated CD4+ T cells, thus explaining why CT,
through its sustained binding on the G-stimulatory protein of the
adenylate cyclase complex, was more effective than FSK alone
at raising IL-4 production.
To confirm that cAMP was the main mediator of the opposite
regulation of IL-2 and IL-4 in activated CD4+ T cells, we
supplemented cultures with Bt2-cAMP, a cAMP analog know to
rapidly diffuse into cells. In dose - response experiments,
Bt2-cAMP increased IL-4 production and reduced IL-2 release
from PMA- and ionomycin-re-stimulated CD4+ T cells to an
extent comparable with levels obtained with CT (data not shown).
A time-course experiment with Bt2-cAMP is shown in Fig. 5. It
shows that IL-2 mRNA levels were lower and IL-4 mRNA higher
in Bt2-cAMP treated cells than in cells without Bt2-cAMP. At all
time points, the lymphokine levels in the supernatants correlated
with IL-2 and IL-4 mRNA accumulation. The parallel increase of
IL-4 and decrease of IL-2 lymphokine accumulation and mRNA
production mediated by cAMP-elevating agents (Figs 2, 3 and
5) indicate that cAMP is likely to influence lymphokine production
directly at the transcriptional level. It is however possible that the
effect on steady state mRNA levels could also be explained by
effects of cAMP on mRNA stability, as reported for IFN-y (35).
IL-5, a mediator of eosinophilia in vivo (36), is another
lymphokine typical for Th2 cells. Since a cAMP-dependent
increase of IL-5 production was previously reported in short-term
T cell lines (15), we examined the effect of cAMP elevation on
IL-5 produced by activated CD4+ T cells re-activated by PMA
and ionomycin. The presence of CT (Fig. 6A) or Bt2-cAMP
(Fig. 6B) both up-regulated IL-5 production but suppressed IL-2
release in the experiments.
Having found that pharmacological cAMP-elevating agents
differentially modulated IL-2 and IL-4 together with IL-5 in CD4+
T cells re-activated with PMA and ionomycin, we then further
assessed whether the lymphokine production of re-activated
CD4+ T cells was similarly regulated in a more physiologic
situation, using PGE2 as a cAMP-elevating agent and
re-activation through the TCR-CD3 complex. In PMA and
ionomycin-re-activated CD4+ T cells (Fig. 7A), PGE2 repro-
duced results obtained with CT and Bt2-cAMP: it inhibited IL-2
and increased IL-4 production in a dose-dependent manner. We
next verified whether activated CD4+ T cells re-activated
through the TCR - CD3 complex were also susceptible to PGE2.
We therefore used plate-bound anti-CD3 to re-stimulate activated
CD4+ T cells. Again, PGE2 up-regulated IL-4 release and
suppressed IL-2 production (Fig. 7B). The effect on IL-4 was less
pronounced than with PMA- and ionomycin-stimulated cells, but
reproducible and significant. Similar results were obtained with
CT and Bt2-cAMP when plate-bound anti-CD3 re-stimulation
was used (data not shown)
As the second messenger cAMP may directly influence IL-2
release in re-activated CD4+ T cells at the transcriptional level,
we finally investigated whether cAMP-elevating agents could
modify known nuclear factors initiating IL-2 transcription. We
therefore prepared nuclear extracts from re-activated CD4+ T
cells stimulated with PMA and ionomycin in the presence of CT,
and performed gel retardation analysis using a-13P-labeled DNA
fragments comprising binding sites for NF-AT and NF-IL-2-A from
the murine IL-2 promoter. CT clearly inhibited the binding of
nuclear factors to the NF-AT binding site, while no modification
400
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Fig. 5. The opposite effect of Btj-cAMP on the production of IL-2 and IL-4 is reflected at the mRNA level. Cells (2 x 106) were stimulated with PMA
and ionomycin in the presence or absence of Bt2-cAMP. At indicated time points, cultures were harvested and immediately centrifuged. Supematants
were assayed for lymphokine production and total mRNA was extracted from pelleted cells. Lymphokine levels are expressed as means =t SD
of triplicate cultures (A). RT-PCR amplifications of specific mRNAs were electrophoresed on 2% agarose gels in the presence of ethidium bromide
(B), after normalization with DHFR amplification products. Differences in lymphokine content of cAMP-treated versus untreated culture supematants
were statistically significant after 4 h (P < 0.01). Lymphokine analysis of four similar experiments and RNA analysis of two similar experiments gave
comparable results.
was seen with the protein complexes on the NF-IL-2-A site (Fig.
8A). Because the NF-AT complex that is generated with the NF-
AT site of the IL-2 promotor contains a pre-existing unit (NF-ATp)
in association with Jun and Fos family proteins, it is possible that
decreased NF-AT binding reflects a decrease in the level of
FosAJun proteins. To test this possibility, we performed a gel shift
assay with nuclear extracts and an oligonucleotide containing
an AP-1 consensus sequence (30), because AP-1 consensus
sequences form complexes containing Jun and Fos family
proteins in nuclear extracts of activated T cells (37). However,
when complexes between an oligonucleotide containing an AP-1
consensus sequence and nuclear extracts from PMA- and
tonomycin-stjmulated T cells were compared with complexes from
PMA, ionomycin and CT incubated cells, no difference was
observed (Fig. 8B). This renders unlikely the possibility that
decreased binding to the NF-AT site induced by CT was due
to diminished Jun/Fos family proteins. Specificity of the DNA
probes was assessed in previous inhibition experiments and has
been previously published (29,30).
Discussion
Here, we have clearly shown that cAMP and cAMP-increasing
reagents differentially regulate IL-2 and the T ^ lymphokines
IL-4 and IL-5. The fact that we found up-regulation of IL-4 by
cAMP, in contrast to previous studies, may be due to the use
of different cell sources. In earlier reports, mainly cell lines with
a fixed lymphokine pattern were used (13-16). In these cells,
activation in the absence of cAMP may already induce maximal
IL-4 production and cAMP may not be able to further augment
the release of IL-4. Alternative explanations may come from
differences in working concentrations of cAMP-elevating agents
(16) or from different kinds of stimulation, such as antigen plus
antigen presenting cell on short-term lines (15). Indeed, since
antigen presenting cell-derived co-stimulatory signals can
selectively regulate IL-2 and IL-4 production (38), it is likely that
cAMP-elevating agents differently affect lymphokine production
in a system where antigen plus antigen presenting cell, rather
than PMA and ionomycin or anti-TCR - CD3 stimulation is used.
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PMA-induced IL-5 production has very recently been reported
to be increased by cAMP in EL-4 cells (39). In contrast to most
previous experiments, we used a polyclonal population of
previously activated CD4+ T cells that may represent an
intermediate stage in T ^ development. In our hands, these
activated CD4+ T cells with an unrestricted lymphokine pattern
could be induced to differentiate into 1^2 cells when Con A and
IL-2 were used as previously described (18). Pharmacological
activation or activation via the TCR - CD3 complex leads to IL-4
and IL-5 production that can be further stimulated by cAMP. Our
hypothesis that in vitro activated CD4+ T cells represent a valid
model for in vivo activated CD4+ T cells is supported by our
observation that freshly isolated CD4+ T cell blasts show the
same susceptibility to cAMP and cAMP-elevating reagents as
in vitro activated CD4+ T cells (M. Lacour and C. Hauser,
manuscript in preparation). cAMP seems also to promote the
development of a T^-fike lymphokine pattern in vivo as recently
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Rfl. 6. IL-5 production from activated CD4+T cells is up-regulated by
CT and Bt2-cAMP. Activated CD4+ T cells (10s) were re-stimulated with
PMA and ionomycin in 200 ?l of culture medium containing the indicated
concentrations of (A) CT or (B) Btj-cAMP. Results represent the
lymphokine content of 24 h supernatarrts and are expressed as means
± SD of triplicate cultures. As compared with controls, IL-4 production
was increased by a ratio of 5.81 at 1 ng/ml CT (A) and a ratio of 6.72
at 50 pM Btj-cAMP (B). Data are representative of three similar
experiments. *P < 0.05, "P < 0.01.
shown by Xu-Amano et al. (40) who used CT as an adjuvant in
an oral immunization protocol.
PGE2 is an extracellular ligand that has been demonstrated
to increase cAMP in CD4+ T cells, and to exert many immuno-
suppressive functions by counteracting T cell activation and
proliferation (41). Here, we show that PGE2 increases IL-4
release in re-activated CD4+ T cells. Most likely, this increase
of IL-4 by PGE2 was due to an elevation of intracellular cAMP
levels. It has recently been reported that some IL-4-induced
effects on endothelial cells are dependent on cAMP (42),
suggesting that cAMP may be a second messenger of the IL-4
receptor, as has been shown in human tonsillar B cells (43). We
therefore added IL-4 during re-stimulation of activated CD4+ T
cells by PMA and ionomycin, and found that IL-4 production was
indeed up-regulated (data not shown). Because IL-4 has been
well documented to autoinduce its production (10,11,44,45), it
is thus possible that IL-4 may autoamplify its expression via a
cAMP-dependent pathway.
Our findings that cAMP-elevating agents promote a Th2-like
pattern of lymphokine production in activated CD4+ T cells also
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Fig. 7. PGE2 up-regulates IL-4 and decreases IL-2 in PMA/ionomycin-
and anti-CD3-re-stimulated CD4+ T cells. Cells (10s) were placed in
200 /il of culture medium containing graded doses of PGE2, and re-
stimulated with either PMA and ionomycin (A) or coated anti-CD3 (B).
Results represent the lymphokine content of 24 h supernatarrts and are
expressed as mean ± SD of triplicate cultures. Data are representative
of three (A) and two (B) experiments. 'P < 0.05, "P < 0.01.
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confirm that PGE2 may play a major role in the regulation of the
immune response. Indeed, PGE2 induces a cascade of events
that all lead to Th2 cell induction and high IgE production by
B cells (reviewed in 46). It may therefore be significant that
monocytes from patients with either hyper-lg E syndrome or
atopic dermatitis secrete abnormally high levels of PGE2 (47,48).
However, it remains unclear whether these findings reflect a
primary or secondary event.
Finally, what are the intracellular cAMP targets relevant for IL-2
and IL-4 production? The decrease of IL-2 gene nuclear trans-
cription induced by PGE2 has been reported to be reverted by
H-8 (49), a competitor for. the ATP-binding site of the catalytic
subunft of the cAMP-dependent protein kinase, PKA (50). In
addition, the same group has recently given evidence that cAMP
inhibits IL-2 promoter activity by interfering with cydosporin A-
sensitive and calcineurin-dependent pathways (51). Another
mechanism of mRNA regulation has been shown by Kaldy et al.
They found that cAMP regulated lympnokine mRNA levels by
modulating their stability (35).
Caldneurin has been demonstrated to be the target of the IL-2
suppressing property of the cyclosporin A - cyclophilin complex
(52,53). It has previously been shown that NF-AT, composed of
Jun and Fos as well as a recently cloned component (54,55),
is also cyclosporin A sensitive (56). Calcineurin was then shown
to be a substrate of NF-AT (57). Calcineurin probably regulates
NF-AT by controlling its translocation from the cytoplasm to the
nucleus. The NF-AT complex plays an important role for IL-2 gene
expression by binding to a proximal promoter element 5'
upstream from the transcription initiation site of IL-2. This NF-AT
site, when occupied by NF-AT, confers increased promoter
activity (58). We therefore tested the hypothesis whether cAMP
suppresses IL-2 expression via a modification of NF-AT. Gel
retardation assays performed with nuclear extracts of activated
T cells and a synthetic NF-AT site demonstrated that CT, when
added to stimulated CD4+ T cells, caused a decrease in NF-
AT binding. Although no functional data are presented with the
presently used system that consists of non-immortalized T cells,
our results suggest that cAMP inhibits IL-2 gene expression via
NF-AT
P/l
CT 0.1
NF-IL2-A
0.1
AP-1
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CT 0.1
1 1
Fig. 8. Interaction of nuclear proteins present in nuclear extracts from activated CD4+ T cells with the NF-AT and NF-IL-2-A binding sites of the
murine IL-2 promoter and an AP-1 consensus sequence. (A) Nuclear extracts from non-stimulated activated CD4+ T cells (lanes 1 and 5) or from
activated CD4+ T cells stimulated with PMA and ionomycin (lanes 2-4 and 6-8) in the presence of 0.1 ng/ml CT (lanes 3 and 7) or 1 ng/ml CT
(lanes 4 and 8) were incubated with ot-^ P-labeted DNA fragments containing the binding sites for NF-AT (lanes 1 -4) or NF-IL-2-A (lanes 5-8)
respectively. Arrows indicate the respective specific complexes. (B) Nuclear extracts from non-stimulated activated CD4+ T cells (lane 1) or from
activated CD4+ T cells stimulated with PMA and ionomyctn (lanes 2-4) in the presence of 0.1 ng/ml CT (lane 3) or 1 ng/ml CT (lane 4) were Incubated
with oe^P-labeled DNA fragments containing the binding site for AP-1 (lanes 1 - 4).
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decreased NF-AT binding. To rule out the possibility that
decreased binding to NF-AT was due to diminished Jun/Fos
family proteins that bind to AP-1 and form a part of the complex
that bind to NF-AT, we compared complexes binding to an AP-1
consensus sequence from CT-treated and control cells. As no
difference was observed, it is unlikely that decreased NF-AT
binding can be explained by decreased Jun/Fos family proteins.
We are currently using immortalized cell lines in order to obtain
functional evidence for this hypothesis.
At present, we have no experimental data to explain as to how
cAMP up-regulates the expression of IL-4. However, it is
interesting to note that several NF-AT-like sites in the IL-4 promoter
have been described (59-61). NF-AT protein complexes bind
to these sites and confer increased promoter activity. It is of
particular interest that in activated Th1 and T ^ cell clones, an
NF-AT species without AP-1 has been identified that binds to an
NF-AT site within the - 7 4 to - 6 7 region of the IL-4 promoter
(62). This site can confer increased IL-4 promoter activity. It is
therefore tempting to speculate that CT caused a shift from NF-AT
containing AP-1 to NF-AT without AP-1, and thus explain the
suppression of IL-2 production and the enhancement of IL-4
release. However, our data with the gel shift experiments using
an AP-1 consensus site cannot support this hypothesis because
Th 2 cells are reported to contain nuclear factors binding to AP-1
sites. To test the possibility that some factors binding to the
mentioned NF-AT site within the IL-4 promoter changed with CT
treatment, we compared complexes forming with an oligo-
nucleotide containing the - 86 to - 60 site of the IL-4 promoter.
However, CT treatment resulted in a decrease of both binding
complexes (data not shown), again not supporting the hypothesis
that CT may shift NF-AT protein from AP-1 rich to AP-1 poor.
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